Trademark Search in Canada

D6DMQ

View On IC.GC.CA

REGISTERED

on 9 Sept 2024

Last Applicant/ Owned by

OTSUKA PHARMACEUTICAL CO. LTD.

2-9 Kanda-Tsukasamachi,Chiyoda-kuTokyo 101-8535

Serial Number

2251510 filed on 25^th Jan 2023

Registration Number

TMA1255496 registered on 9^th Sept 2024

Registration expiry Date

25^th Jan 2033

D6DMQ

Trademark usage description

pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of agita Read More

Classification Information

Class [005]
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of agitation in patients with Alzheimer's dementia, negative symptoms of schizophrenia, and traumatic brain injury.

Classification kind code

Mark Details

Serial Number

2251510

Mark Type

Trademark

Legal History

Action Taken	Status
Submitted for opposition 42 on 19^th Jun 2024	Advertised
Submitted for opposition 26 on 24^th May 2024	Approved
Submitted for opposition 27 on 24^th May 2024	Approval Notice Sent
Submitted for opposition 22 on 15^th May 2024	Search Recorded
Submitted for opposition 256 on 13^th Feb 2024	Notification of Possible Opposition Sent
Submitted for opposition 257 on 13^th Apr 2023	Designation Notification - Madrid Protocol
Submitted for opposition 1 on 12^th Apr 2023	Created
Submitted for opposition 31 on 12^th Apr 2023	Formalized
Submitted for opposition 228 on 25^th Jan 2023	International Registration
Submitted for opposition 30 on 25^th Jan 2023	Filed

D6DMQ

Classification Information

Class [005]Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of agitation in patients with Alzheimer's dementia, negative symptoms of schizophrenia, and traumatic brain injury.

Classification kind code

Mark Details

Serial Number

Mark Type

Legal History

Class [005]
Pharmaceutical preparations for the treatment of central nervous system diseases and disorders; pharmaceutical preparations for the treatment of agitation in patients with Alzheimer's dementia, negative symptoms of schizophrenia, and traumatic brain injury.